Staff
Editorial Board
David C. Helfgott, MD, is assistant attending physician at The New York-Presbyterian Hospital and assistant clinical professor of medicine at Weill Cornell Medical College in New York City.
Stanford T. Shulman, MD, is a Virginia H. Rogers Professor of Pediatric Infectious Diseases at Northwestern University Feinberg School of Medicine and is associated with Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.
Michael Tapper, MD, is director of the Division of Infectious Diseases at Lenox Hill Hospital in New York City.
Editorial Staff
Editor
Editorial Director
Kathleen Tulley
Email: kathleen.tulley@haymarketmedia.com
Clinical Strategists
Corinna Panlilio Sison, MD
Email: corinna.panlilio@haymarketmedia.com
Mita Patel Tewar, MD
Email: mita.tewar@haymarketmedia.com
Art
Group Art Director, Haymarket Medical
Jennifer Dvoretz
Digital Designer
Bobby Farrell
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- Examining the Effects of Nonmedical Exemptions for Vaccinations
- Delays in Lactate Testing Associated With Delayed Antibiotics, Increased Mortality in Sepsis
- Chronic Hepatitis C Virus Infection Rates by Race Differ by State
- Parental Oral Secretions a Potential Source for Epstein-Barr Virus in Children
- Mandatory Influenza Vaccination Advised for Healthcare Personnel in VA, Non-VA Hospitals
- The Role of Dietary Trehalose in the Clostridium difficile Epidemic
- Delays in Lactate Testing Associated With Delayed Antibiotics, Increased Mortality in Sepsis
- Etiology of Acute Liver Failure Can Yield Surprising Findings
- How Many Chances Are Too Many? Treating Recurrent Infective Endocarditis in IV Drug Users
- Delay of Lactate Draws in Sepsis Ups Risk of In-Hospital Death
- Normal on-Treatment ALT Linked to Reduced Hepatic Events in Hepatitis B
- Parents Say Cancer Prevention Best Reason for HPV Vaccination
- Should Metronidazole Be Recommended for Mild Clostridium difficile Infections?
- Effective Clinical Pharmacist Specialist Management of Direct-Acting Antiviral Treatment for HCV
- Deferred Treatment With Sofosbuvir-Velpatasvir-Voxilaprevir in Chronic HCV
